Phase 1 N=41 A Study of LY3025876 in Healthy Volunteers
Healthy Volunteers
Primary: Number of Participants With 1 or More Drug-related Adverse Events or Any Serious Adverse Events — 0; 0; 0; 0 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=27 Pralatrexate and Fluorouracil in Treating Patients With Recurrent Solid Tumors
Unspecified Adult Solid Tumor, Protocol Specific
Primary: Recommended Dose of PDX Given With a Fixed Dose of 5-FU — 148 mg per meter square
Phase 1 N=15 A Study of Blosozumab (LY2541546) in Postmenopausal Female Participants
Osteoporosis, Postmenopausal
Primary: Pharmacokinetics (PK): Maximum Concentration (Cmax) of Blosozumab — 59.8 picomoles per milliliter
Phase 1 N=3 T1DM Immunotherapy Using CD4+CD127lo/-CD25+ Polyclonal Tregs
Type 1 Diabetes Mellitus
Primary: Adverse Events (AEs) as a Measure of Safety and Tolerability — 25; 19; 31; 29 adverse events
Phase 1 N=14 Pediatric Pharmacokinetic (PK) Study of EXE844 Otic Suspension in Otitis Media at the Time of Tympanostomy Tube Insertion (OMTT)
Otitis Media With Effusion in Children · Otitis Media Recurrent
Primary: Maximum Analyte Plasma Concentration (Cmax) — 2.44; 1.61 ng/mL
Phase 1 N=39 Therapeutic Vaccination for Patients With HPV16+ Cervical Intraepithelial Neoplasia (CIN2/3)
HPV16 Positive · Cervical Intraepithelial Neoplasia (CIN 2/3)
Primary: Number of Participants With Related Serious Adverse Events — 0; 0; 0; 0 Participants
Phase 1 N=14 Intra-arterial Melphalan in Treating Younger Patients With Unilateral Retinoblastoma
Unilateral Retinoblastoma
Primary: Number of Patients Experiencing Feasibility Failure — 4 participants
Phase 1 N=324 Pharmacokinetics and Safety in Healthy Volunteers
Healthy
Primary: Area Under the Concentration Time Curve (AUC) From Time Zero to Infinity (AUC 0-∞) of BI 695501, US-licensed Humira® or EU-approved Humira® — 2630; 2470; 2650 microgram…
Phase 1 N=38 Safety, Tolerability, and Pharmacokinetics of SAB-301 in Healthy Adults
Middle East Respiratory Syndrome Coronavirus
Primary: Number of Participants Having Adverse Events — 1; 2; 2; 4 Participants
Phase 1 N=42 Comparative Pharmacokinetics of AFOLIA and US Gonal-f® RFF Redi-ject After Single Subcutaneous Application
Healthy Volunteers
Primary: Baseline Corrected FSH Area Under the Serum Concentration-time Curve From Zero to the Last Quantifiable Measurement [AUC(0-last)] — 18.96; 10.47 nanograms*hours/mL…
Phase 1 N=30 Reducing Dyskinesia in Parkinson's Disease With Omega-3 Fatty Acids
Parkinson's Disease
Primary: Efficacy of DHA - Change in Blood ng/dL Levels — 102.18; -13.20 ng/dL - Blood
Phase 1 N=99 Study of the Safety, and Sperm and Gonadotropin Suppression of a Contraceptive Gel in Normal Men
Contraception
Primary: The Number of Men Who Have Suppression of Sperm Production ≤1Million/mL Million/mL When Using a Daily Regimen of Nestorone® Gel (0, 8 or 12 mg) and Testosterone Gel…
Phase 1 N=153 An Investigation of Early Life Stress and Depression
Major Depressive Disorder (MDD) · History of Childhood Sexual Abuse (CSA)
Primary: Dopamine Active Transporter Binding Potential — 3.191; 3.161; 3.175; 3.216 Ratio
Phase 1 N=32 Safety, Tolerability and Pharmacokinetics of BIIB118 (PF-05251749)
Healthy
Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) — 0; 2; 0; 1 participants
Phase 1 N=28 Ibuprofen Suspension Bioequivalence Study
Healthy Volunteer Study
Primary: Maximum Plasma Concentration (Cmax) — 37499.938; 26207.273; 34752.646; 26377.382 ng/mL